Camilla Eckert-Lind, Amani Meaidi, Brian Claggett, Niklas Dyrby Johansen, Mats Christian Højbjerg Lassen, Kristoffer Grundtvig Skaarup, Michael Fralick, Manan Pareek, Jens Ulrik Stæhr Jensen, Christian Torp-Pedersen, Gunnar Gislason, Tor Biering-Sørensen, Daniel Modin
{"title":"曾发生静脉血栓栓塞的妇女的复发性静脉血栓栓塞与阴道雌二醇:巢式病例对照研究。","authors":"Camilla Eckert-Lind, Amani Meaidi, Brian Claggett, Niklas Dyrby Johansen, Mats Christian Højbjerg Lassen, Kristoffer Grundtvig Skaarup, Michael Fralick, Manan Pareek, Jens Ulrik Stæhr Jensen, Christian Torp-Pedersen, Gunnar Gislason, Tor Biering-Sørensen, Daniel Modin","doi":"10.1111/ejh.14287","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Objectives</h3>\n \n <p>Whether vaginal estradiol use is associated with an increased risk of recurrent venous thromboembolism (VTE) in women with prior VTE is unknown. We sought to evaluate the association between vaginal estradiol use and recurrent VTE in women with prior VTE.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>We performed a nationwide nested case–control study among 44 024 women aged ≥45 years who developed a first VTE without a history of vaginal estrogen use prior to VTE diagnosis. Cases with recurrent VTE were matched 1:2 on birth year with controls using incidence density sampling. Exposure to vaginal estradiol tablets was categorized into current use (0–2 months before index), prior use (2–24 months before index) and past use (more than 24 months prior to index).</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>We identified 5066 cases and 10 127 age-matched controls. In fully adjusted analysis vaginal estrogen was not associated with recurrent VTE with a hazard ratio of 0.75, <i>p</i> = .07 for current use, 0.83, <i>p</i> = .13 for prior use, and 1.24, <i>p</i> = .06 for past use.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>Use of vaginal estradiol tablets in women with prior VTE was not associated with an increased rate of recurrent VTE. Our study indicates that vaginal estradiol therapy is unlikely to increase risk of recurrent VTE in women with prior VTE.</p>\n </section>\n </div>","PeriodicalId":11955,"journal":{"name":"European Journal of Haematology","volume":"113 6","pages":"745-750"},"PeriodicalIF":2.3000,"publicationDate":"2024-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Recurrent venous thromboembolism and vaginal estradiol in women with prior venous thromboembolism: A nested case–control study\",\"authors\":\"Camilla Eckert-Lind, Amani Meaidi, Brian Claggett, Niklas Dyrby Johansen, Mats Christian Højbjerg Lassen, Kristoffer Grundtvig Skaarup, Michael Fralick, Manan Pareek, Jens Ulrik Stæhr Jensen, Christian Torp-Pedersen, Gunnar Gislason, Tor Biering-Sørensen, Daniel Modin\",\"doi\":\"10.1111/ejh.14287\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n \\n <section>\\n \\n <h3> Objectives</h3>\\n \\n <p>Whether vaginal estradiol use is associated with an increased risk of recurrent venous thromboembolism (VTE) in women with prior VTE is unknown. We sought to evaluate the association between vaginal estradiol use and recurrent VTE in women with prior VTE.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Methods</h3>\\n \\n <p>We performed a nationwide nested case–control study among 44 024 women aged ≥45 years who developed a first VTE without a history of vaginal estrogen use prior to VTE diagnosis. Cases with recurrent VTE were matched 1:2 on birth year with controls using incidence density sampling. Exposure to vaginal estradiol tablets was categorized into current use (0–2 months before index), prior use (2–24 months before index) and past use (more than 24 months prior to index).</p>\\n </section>\\n \\n <section>\\n \\n <h3> Results</h3>\\n \\n <p>We identified 5066 cases and 10 127 age-matched controls. In fully adjusted analysis vaginal estrogen was not associated with recurrent VTE with a hazard ratio of 0.75, <i>p</i> = .07 for current use, 0.83, <i>p</i> = .13 for prior use, and 1.24, <i>p</i> = .06 for past use.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Conclusion</h3>\\n \\n <p>Use of vaginal estradiol tablets in women with prior VTE was not associated with an increased rate of recurrent VTE. Our study indicates that vaginal estradiol therapy is unlikely to increase risk of recurrent VTE in women with prior VTE.</p>\\n </section>\\n </div>\",\"PeriodicalId\":11955,\"journal\":{\"name\":\"European Journal of Haematology\",\"volume\":\"113 6\",\"pages\":\"745-750\"},\"PeriodicalIF\":2.3000,\"publicationDate\":\"2024-08-08\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"European Journal of Haematology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1111/ejh.14287\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"HEMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Haematology","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/ejh.14287","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"HEMATOLOGY","Score":null,"Total":0}
Recurrent venous thromboembolism and vaginal estradiol in women with prior venous thromboembolism: A nested case–control study
Objectives
Whether vaginal estradiol use is associated with an increased risk of recurrent venous thromboembolism (VTE) in women with prior VTE is unknown. We sought to evaluate the association between vaginal estradiol use and recurrent VTE in women with prior VTE.
Methods
We performed a nationwide nested case–control study among 44 024 women aged ≥45 years who developed a first VTE without a history of vaginal estrogen use prior to VTE diagnosis. Cases with recurrent VTE were matched 1:2 on birth year with controls using incidence density sampling. Exposure to vaginal estradiol tablets was categorized into current use (0–2 months before index), prior use (2–24 months before index) and past use (more than 24 months prior to index).
Results
We identified 5066 cases and 10 127 age-matched controls. In fully adjusted analysis vaginal estrogen was not associated with recurrent VTE with a hazard ratio of 0.75, p = .07 for current use, 0.83, p = .13 for prior use, and 1.24, p = .06 for past use.
Conclusion
Use of vaginal estradiol tablets in women with prior VTE was not associated with an increased rate of recurrent VTE. Our study indicates that vaginal estradiol therapy is unlikely to increase risk of recurrent VTE in women with prior VTE.
期刊介绍:
European Journal of Haematology is an international journal for communication of basic and clinical research in haematology. The journal welcomes manuscripts on molecular, cellular and clinical research on diseases of the blood, vascular and lymphatic tissue, and on basic molecular and cellular research related to normal development and function of the blood, vascular and lymphatic tissue. The journal also welcomes reviews on clinical haematology and basic research, case reports, and clinical pictures.